Please login to the form below

Not currently logged in
Email:
Password:

GSK appoints Dr Richard Jones to Rare Disease Unit

He joins the pharma company from Genzyme

Richard Jones - GSK, global commercial leader, rare disease unitGlaxoSmithKline (GSK) has appointed Dr Richard Jones to its Rare Disease Unit in a role that will see him guide commercial strategy across CNS, neuomuscular disorders, rare malignancies and haematology franchises.

He joins the pharma company as global commercial leader (CNS, muscular disorders, rare malignancies and haematology) from Genzyme, where he served as director, EMEA oncology and transplant.

In this position Dr Jones was commercially responsible for the portfolio of assets as well as managing the integration and transition of business development projects.

Prior to Genzyme, he served at Shire in various international commercial and therapy area project lead roles and then worked at the MSI consultancy.

GSK's Rare Disease Unit was set up in February 2010 to leverage its existing capabilities and partnerships and establish further in-licensing opportunities.

In April of that year the pharma company signed a deal $1.5bn potentially worth with Isis Pharmaceuticals to develop new drugs for rare and serious diseases using Isis' antisense drug discovery platform.

Meanwhile, in August 2011 GSK signed a deal with Italian biotech company MolMed to develop a production process for an ex vivo gene therapy for Adenosine Deaminase Deficiency - Severe Combined Immune Deficiency (ADA-SCID), commonly referred to as 'bubble boy disease'.

16th January 2012

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
KVA Digital

KVA is an award winning full-service digital communications & brand experience agency. Our healthcare expertise blends creative ‘outside-the-box’ thinking with...

Latest intelligence

clinical research org
The important role of CROs in shaping the future of clinical research across Europe
Looking at the impact of COVID-19 on clinical research activities...
What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...

Infographics